CIBC Asset Management Inc Takes $201,000 Position in Omnicell, Inc. (NASDAQ:OMCL)

CIBC Asset Management Inc acquired a new stake in Omnicell, Inc. (NASDAQ:OMCL) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 4,505 shares of the company’s stock, valued at approximately $201,000.

Other hedge funds also recently modified their holdings of the company. Van ECK Associates Corp lifted its position in Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after acquiring an additional 315 shares during the last quarter. Curi RMB Capital LLC lifted its position in Omnicell by 0.7% during the third quarter. Curi RMB Capital LLC now owns 88,815 shares of the company’s stock worth $3,872,000 after acquiring an additional 651 shares during the last quarter. KBC Group NV lifted its position in Omnicell by 60.8% during the fourth quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after acquiring an additional 778 shares during the last quarter. New York State Teachers Retirement System lifted its position in Omnicell by 2.4% during the fourth quarter. New York State Teachers Retirement System now owns 61,974 shares of the company’s stock worth $2,759,000 after acquiring an additional 1,432 shares during the last quarter. Finally, 1620 Investment Advisors Inc. lifted its position in Omnicell by 230.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after acquiring an additional 1,542 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on OMCL. Craig Hallum raised their price objective on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Barclays raised their price objective on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Benchmark reiterated a “buy” rating and issued a $62.00 price target on shares of Omnicell in a research report on Tuesday, February 4th. Wells Fargo & Company dropped their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, Bank of America dropped their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Omnicell currently has a consensus rating of “Hold” and an average price target of $52.33.

Omnicell Stock Up 0.6 %

NASDAQ OMCL opened at $39.73 on Thursday. The company has a 50 day moving average of $42.65 and a 200-day moving average of $43.85. The company has a market cap of $1.84 billion, a price-to-earnings ratio of 147.15, a PEG ratio of 7.53 and a beta of 0.78. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $55.74.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, equities research analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Insider Activity at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the transaction, the director now directly owns 58,427 shares of the company’s stock, valued at $2,763,597.10. This trade represents a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 2.64% of the stock is currently owned by insiders.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.